The $450M Copaxone figure in #msg-67293937 takes into account the (less than certain) probability of success and the sharing of profits with NVS. The figure is probably near the low end of what’s reasonable, but I was trying to be conservative.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”